Trial Profile
A study of INT-747 (6-ethyl chenodeoxycholic acid [6-ECDCA]) in combination with ursodeoxycholic acid (UDCA [URSO]) in patients with primary biliary cirrhosis (PBC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Obeticholic acid (Primary) ; Ursodeoxycholic acid
- Indications Primary biliary cirrhosis
- Focus Therapeutic Use
- Acronyms POISE
- Sponsors Intercept Pharmaceuticals
- 11 Jan 2024 Status changed from completed to discontinued. (Study stopped by sponsor due to administrative reasons)
- 13 Sep 2022 Results published in the Gastroenterology
- 26 Jun 2022 Results of an analysis assessing event-free survival in OCA-treated patients in POISE compared to non-OCA treated external controls presented at The International Liver Congress 2022